Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Radoff-JEC Group, which reports owning approximately 7.7% of Seer’s (NASDAQ: SEER) outstanding common stock, is urging stockholders to use the WHITE proxy card to elect its three independent nominees, Howard H. Berman, Ph.D., Luis E. Rinaldini and Joshua S. Horowitz, to Seer’s Board.
According to Radoff-JEC Group, all three major independent proxy advisors – ISS, Glass Lewis and Egan-Jones – recommend voting for its nominees, withholding support from certain incumbent directors, and voting against Seer’s Tax Benefit Preservation Plan. The group cites Seer’s share-price decline of about 97% since its 2020 IPO and advocates installing new independent directors to lead a robust, transparent review of strategic alternatives, including a potential sale of the company.
Summary not available.
Seer (Nasdaq: SEER)/b) announced that a Special Committee of its Board, composed of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected an unsolicited, non-binding proposal dated July 1, 2026 from Chair and CEO Omid Farokhzad, M.D. to acquire all outstanding shares of Seer’s Class A common stock for
The Special Committee, advised by independent advisors, determined the proposal is not in the best interests of stockholders because it undervalues Seer and does not reflect its long-term growth prospects. It also concluded that the CVRs, intended to allow stockholders to benefit from future developments related to Seer’s technology, are insufficient to fully value Seer and its growth potential.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Seer (Nasdaq: SEER) received an unsolicited, non-binding proposal from Chair and CEO Omid Farokhzad, M.D. to acquire all outstanding Class A common shares for $2.45 in cash per share plus two contingent value rights.
A Special Committee of independent directors will evaluate this proposal and other strategic alternatives with independent financial and legal advisors. No stockholder action is required now.